QIR Suite vs Tempus ECG-AF
AI Verdict
Choose QIR Suite if…
Choose QIR Suite if your clinical practice requires in-depth, quantitative analysis of cardiovascular conditions using advanced imaging modalities like MRI and CT. This tool is ideal for precisely evaluating known or suspected cardiac pathologies, quantifying over 100 clinical parameters, and assessing blood flow and strain to support detailed diagnosis and prognosis.
View QIR Suite →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, utilizing standard 12-lead ECGs. This solution is best suited for screening asymptomatic or at-risk populations to enable earlier intervention and follow-up, rather than for diagnosing existing conditions.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | QIR Suite | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact for pricing | Contact vendor |
| Deployment | Locally on dedicated hardware | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF is designed as a software solution integrated into existing healthcare systems and compatible with common ECG machines, suggesting easier adoption into clinical workflows. QIR Suite's local deployment on dedicated hardware might introduce more IT overhead and a steeper learning curve for its complex imaging analysis features.
Clinical Value
Tempus ECG-AFTempus ECG-AF has explicit FDA clearance for its specific purpose of identifying patients at risk for AF, addressing a critical need for early detection of a prevalent condition. While QIR Suite offers comprehensive quantitative imaging analysis, its broad application and less specific FDA clearance information make its immediate clinical impact harder to compare directly against Tempus's targeted, validated solution.
Pricing & Value
Tempus ECG-AFTempus ECG-AF provides a clear financial value proposition with established CMS reimbursement codes and a defined Medicare rate, making it easier for healthcare facilities to justify and fund its adoption. QIR Suite's pricing is less transparent, with only general models (license/subscription) specified, offering no immediate insight into its economic value.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are non-negotiable requirements for healthcare enterprises. Its integration-focused deployment and compatibility with major ECG systems also enhance its readiness. QIR Suite's lack of specified HIPAA compliance and BAA, along with local hardware deployment, presents potential hurdles for enterprise adoption.
Innovation
QIR SuiteQIR Suite demonstrates broader innovation by applying AI to complex multi-modal imaging (MR and CT) for comprehensive quantitative analysis of over 100 clinical parameters, including advanced metrics like myocardial perfusion and strain. Tempus ECG-AF offers targeted innovation in predicting AF risk from standard ECGs, which is valuable but less expansive in its technical scope.
Support & Docs
Tempus ECG-AFWhile neither tool provides explicit details on support and documentation quality, Tempus ECG-AF's explicit HIPAA compliance, BAA availability, and FDA clearance imply a more mature product with robust regulatory documentation and likely a structured support framework. The lack of such specifications for QIR Suite makes it difficult to assess its support readiness.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | QIR Suite | Tempus ECG-AF |
|---|---|---|
| Name | QIR Suite | Tempus ECG-AF |
| Company | CASIS Cardiac Simulation & Imaging Software | Tempus AI, Inc. |
| Description | AI-based medical imaging analysis software for cardiovascular conditions, offering quantitative evaluation of MR and CT images to support diagnosis and prognosis. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Primary Modality | MR and CT images | 12-lead ECG recordings |
| Key Features | AI-based analysis of MR and CT examinations; Detection of heart regions and pathological areas; Quantification of over 100 clinical parameters; Automatic segmentation; Blood flow/velocities quantification; Pathological volumes detection and quantification; Semi-quantification of myocardial perfusion; Strain quantification | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients |
Videos
Demos, reviews, and walkthroughs featuring QIR Suite and Tempus ECG-AF.